Drug intelligence / Profile preview

NGM217

Development stage: Unknown
Lead developer: NGM Biopharmaceuticals
Modality: Antibody-Based Therapeutics
Administration: Injection

Overview

NGM217 is an investigational long-acting antibody therapeutic developed by NGM Biopharmaceuticals for autoimmune diabetes. It binds an undisclosed target, so its precise molecular mechanism has not been publicly described, but it was positioned as an immunology-oriented biologic for diabetes treatment. NGM217 completed a Phase 1 clinical study in adults with autoimmune diabetes in 2020, where it was reported to be well tolerated, after which NGM Biopharmaceuticals suspended further activities on the program to prioritize other pipeline assets. NGM Biopharmaceuticals retained worldwide commercial rights.

Beyond the preview

Go deeper on NGM217.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NGM217.

Explore the full profile